Universal Health Services stock (US9139031002): Analyst consensus points to moderate upside potential

Universal Health Services shares on the NYSE have been trading near the mid-140 USD range going into June 2026, while updated analyst data show a consensus hold rating and a wide range of 12?month price targets for the US hospital operator.

Universal Health Services shares have recently been changing hands in the mid-140 USD range on the New York Stock Exchange, with MarketBeat data indicating a closing price of USD 145.78 on 05/29/2026 for the UHS ticker in the United States. According to the same source, the stock was up to around USD 147 in extended trading on that date, underlining that UHS remains actively traded on its home US market as the new month begins, even after a notable decline from levels above USD 200 earlier in 2026.

Based on MarketBeat information, Universal Health Services started 2026 at about USD 217.94 per share, meaning that by late May the stock had fallen roughly one third to the USD 145.78 level on the NYSE as of 05/29/2026. The company therefore enters June with a significantly lower market valuation than at the start of the year, although trading volumes and extended-session quotes cited by MarketBeat as of 05/29/2026 confirm that liquidity in the US listing remains solid for this S&P 500 hospital operator.

For investors in Germany following US equities, Universal Health Services is also available over-the-counter on venues such as Tradegate, where it is quoted in euros and tracks the primary NYSE price in USD. While liquidity in Germany is typically thinner than in the United States, the additional listing route provides a way for euro-based investors to access the UHS share without trading directly on the home US exchange.

According to MarketBeat’s stock forecast page for Universal Health Services as of late May 2026, earnings per share are expected to grow by around 8.31% over the coming year, from USD 23.34 to USD 25.28 per share. This EPS growth projection, combined with the prevailing NYSE share price of USD 145.78 on 05/29/2026, feeds into the company’s valuation metrics and is one of the factors underlying the analyst community’s view on the US-based healthcare stock.

MarketBeat’s data on valuation and performance indicate that Universal Health Services is trading at a price-to-earnings ratio that is below the broader market average as of 05/29/2026, which reflects both the year-to-date share price pullback and expectations that earnings will continue to expand in the coming periods. The same source points out that the stock’s significant retreat from its early-2026 high has created a gap between current market pricing and longer-term analyst targets, although opinions among research houses differ on how quickly this gap might narrow.

On 10/03/2023, Wells Fargo analyst Stephen Baxter resumed coverage of Universal Health Services with an Equal-Weight rating and a USD 165.00 price target, as reported by GuruFocus on that date. In the accompanying commentary, GuruFocus noted that Wells Fargo’s USD 165 target pointed to moderate upside potential from the stock’s then-prevailing trading level, while also reflecting a cautious stance on execution and sector dynamics within the US healthcare provider space.

More recently, MarketBeat’s consolidated forecast for Universal Health Services as of late May 2026 shows an average 12-month price target of about USD 221.56 across 18 Wall Street research analysts. The same MarketBeat forecast cites a high target of USD 310.00 and a low target of USD 185.00, implying that the analyst community sees a wide range of possible outcomes for UHS shares while still expecting upside from the USD 145.78 closing price on 05/29/2026.

According to the MarketBeat analyst consensus data as of 05/29/2026, the overall rating on Universal Health Services shares is categorized as “hold” across the 18 covering analysts. This means that, although the average price target of roughly USD 221.56 suggests potential appreciation of around 52% from the late-May NYSE close, the balance of ratings still points to a more neutral positioning rather than a broad-based conviction buy stance on the US-listed hospital group.

Other individual price targets underscore the dispersion of views. GuruFocus has highlighted a UBS valuation scenario in which the firm reiterates a Buy view on Universal Health Services with a USD 310.00 price target, representing the upper end of the range cited by MarketBeat as of May 2026. At the same time, the existence of lower targets around USD 185.00 within the 18-analyst sample illustrates that some research houses see a more modest upside path from the USD 145.78 share price recorded on the NYSE as of 05/29/2026.

On its stock overview page, MarketBeat notes that Universal Health Services’ shares had declined by roughly 33.1% from the start of 2026, when the price was around USD 217.94, to the USD 145.78 level at the end of May 2026. In that context, the consensus upside of nearly 52% embedded in the USD 221.56 average target would, if realized, essentially retrace the bulk of the year-to-date weakness, though actual future performance will depend on the company’s earnings delivery, reimbursement environment, and broader US healthcare sector trends.

The MarketBeat data also show that Universal Health Services carries a price target spread that is considerably wide, which often indicates differing assumptions among analysts about hospital admissions growth, pricing, labor costs, and capital allocation in the United States. For a US-based operator like UHS, developments in domestic regulatory policy, insurance coverage, and macroeconomic conditions could all influence whether the share price moves closer to the upper or lower end of the USD 185.00 to USD 310.00 target band in the year ahead.

As a reference point, the MarketBeat forecast page emphasizes that the consensus rating of “hold” for Universal Health Services comes from 18 distinct Wall Street research analysts. The classification reflects the fact that the group includes a mix of positive, neutral, and more cautious ratings, and that the average outcome does not tilt decisively toward either a strong buy or an outright sell signal, even though several banks, such as UBS, have expressed more constructive long-term views through higher targets like USD 310.00.

The Wells Fargo Equal-Weight recommendation with a USD 165.00 price objective, as discussed in the October 2023 GuruFocus article, remains a relevant data point within this landscape because it is broadly consistent with the idea of moderate upside but not a strong conviction overweight. In that 10/03/2023 note, Wells Fargo stated that its 2026 EBITDA estimate for Universal Health Services was unchanged, linking the rating and target to a balanced assessment of operational execution and sector risk rather than a call for dramatic multiple expansion.

From a valuation perspective, GuruFocus has also commented on Universal Health Services’ GF Value, which it cited as approximately USD 226.87 at a reference date when the share price was near USD 145.17. That analysis suggested that the stock appeared significantly undervalued at the time, with GuruFocus calculating a margin of safety of about 36.0% between the GF Value metric and the prevailing market price. While the GF Value is a proprietary estimate rather than a traditional broker price target, it nonetheless provides an additional lens on longer-term valuation for the US healthcare operator.

For investors looking at the US market, these various data points collectively show that Universal Health Services is viewed as a company with solid earnings growth expectations and potentially attractive valuation metrics, but one where sector-specific risks and cost pressures temper the enthusiasm of some analysts. The fact that the consensus rating is “hold” while the average target implies more than 50% upside from the 05/29/2026 closing price underscores the nuanced stance of the research community toward this NYSE-listed US hospital operator.

In the context of the broader US stock market, Universal Health Services’ share price performance and analyst coverage situate the company among a group of healthcare providers that have faced volatility in 2026 amid changing expectations for reimbursement and labor dynamics. The combination of a material year-to-date decline, a below-market P/E ratio, and a range of targets stretching from USD 185.00 to USD 310.00 illustrates how investor sentiment on the US hospital sector can diverge even when underlying earnings forecasts, such as the 8.31% projected EPS growth to USD 25.28, remain positive.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: UHS
• Sector/industry: Healthcare providers and hospital operations
• Headquarters/country: King of Prussia, United States
• Core markets: Acute care hospitals and behavioral health facilities primarily in the United States and select international locations
• Key revenue drivers: Patient volumes, reimbursement rates, and occupancy levels across acute care and behavioral health services
• Home exchange/listing venue: New York Stock Exchange (UHS)
• Trading currency: USD

Universal Health Services: core business model

Universal Health Services operates a broad network of acute care hospitals and behavioral health facilities, generating most of its revenue from inpatient and outpatient services that depend on patient volumes, payer mix, and negotiated reimbursement rates in its core US markets.

What banks and research houses say about Universal Health Services

Analyst data compiled by MarketBeat as of late May 2026 show that 18 Wall Street research houses cover Universal Health Services, with the consensus recommendation categorized as “hold” and an average 12-month price target of roughly USD 221.56, compared with the USD 145.78 NYSE close on 05/29/2026. Within that sample, the highest forecasted target of USD 310.00 reflects a more optimistic scenario on earnings and valuation, while the lowest target of USD 185.00 embodies a more cautious view on the US hospital operator’s near-term upside from current trading levels.

A notable individual example is the Wells Fargo Equal-Weight rating with a USD 165.00 price target, which was set when coverage was resumed on 10/03/2023, as reported by GuruFocus. That target sits below the current MarketBeat average but above the late-May 2026 share price, highlighting how some banks see scope for moderate appreciation without assuming that the stock will reach the top end of the USD 185.00 to USD 310.00 target band in the short term.

Conclusion

Universal Health Services enters June 2026 with its NYSE-listed shares trading in the mid-140 USD range, down sharply from the start of the year yet supported by active trading on the home US exchange. Analyst data compiled by MarketBeat and individual views from banks such as Wells Fargo and UBS point to a consensus hold stance paired with a wide band of 12-month targets between USD 185.00 and USD 310.00, with an average around USD 221.56 implying material potential upside from the 05/29/2026 close if earnings forecasts are met. For market participants following the US healthcare provider sector, the stock’s combination of projected EPS growth, below-market valuation multiples, and divergent research targets will likely keep UHS in focus as new financial and regulatory data points emerge over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.